The International Papillomavirus Society (IPVS) supports best practice and evidence-based research, strategies, and policies to prevent HPV-related diseases worldwide.

With the recent call from the World Health Organization (WHO) to global entities to work towards the elimination of cervical cancer globally as a public health problem, a call supported by IPVS [1], it is vital that principles of equity are central to activity in all countries developing strategies to eliminate cervical cancer as a public health problem. This call for equity is outlined in the related IPVS Policy Statement 'Equity in cervical cancer prevention for all women'.

This statement recognises the unequal burden from cervical cancer and other HPV-related diseases that Indigenous peoples face in many areas of the world. With an estimated 370 million Indigenous peoples in 90 countries globally [2], it is paramount that the HPV research and practice communities support culturally appropriate best practices in research and policy to reduce this burden of disease. This statement outlines the origins of this burden, the fundamental requirement to work with Indigenous peoples to reduce this burden, and makes recommendations for actions.

1. An inequitable disease burden

Health inequities for Indigenous peoples, including disparities in cervical cancer and other HPV-related diseases, are rooted in systemic disadvantage including reduced access to health care, culturally inappropriate models of health care, lack of support for Indigenous workforce capacity building, and, in many countries, trauma and disenfranchisement due to colonisation and ongoing dispossession from traditional land and practices [2–8].

Cervical cancer, the most common HPV-related cancer, disproportionately affects Indigenous women who often have higher incidence and mortality rates than other women in their regions. In high-income countries such as Australia, New Zealand, Canada, and some regions of the USA, cervical cancer incidence rates are 2–3.5 times
greater, and mortality rates 2.5 to 4 times greater among Indigenous populations than non-Indigenous populations [9–12].

The true extent of the burden of HPV-related cancers among Indigenous peoples, especially in less-resourced regions such as Latin America, is largely unknown and may be substantially under-estimated due to insufficient data collection [2,13]. To answer the WHO call to eliminate cervical cancer, these inequities must be addressed [14].

2. Best practice and principles in reducing Indigenous health inequities

To achieve equitable health outcomes for Indigenous peoples, strategies are required that consider co-creation of methods and tools, that acknowledge the importance of shared data ownership, and include Indigenous “ways of being, doing, and knowing”, i.e., Indigenous beliefs, practices and knowledge systems; and determinants of responsibility, ‘relationships’ and ‘respect’ [15]. Indigenous leadership is key to developing prioritisation of research focus and methods leading to solutions that are acceptable, appropriate and sustainable, incorporating the WHO health rights platform and best practice principles [16–19].

3. Recommendations for action to reduce Indigenous HPV-related health burden

IPVS supports action by IPVS members and stakeholders (healthcare and research communities, research funding bodies, governments and policy makers) to:

- Acknowledge the fundamental right of Indigenous peoples to equal protection against, and treatment of, HPV-related diseases consistent with the United Nations Declaration on the Rights of Indigenous Peoples [18];
- Develop meaningful respectful partnerships with Indigenous researchers, leaders and communities to conduct work addressing data quality, policy, program and research development in relation to HPV-related disease and HPV Indigenous workforce capacity development;
- Ensure that HPV related issues affecting Indigenous people are presented at relevant forums.

4. Developed by the International Indigenous HPV Alliance (IIHpVA) members

Prof. Beverley Lawton, O.N.Z.M., NZ (IIHpV Chair); Dr. Margaret Heffernan, O.A.M., Australia (Founding committee member); Dr. George Wurtak, Canada (Founding IIHpVA Chair); Dr. Marc Steben, Canada; Pema Lhaki, Nepal (Founding committee member); Dr. Fiona Cram, NZ (Founding committee member); Dr. Magaly Blas, Peru, Latin America (Founding committee member); A/Prof. Merilyn Hibma, NZ; Ms Anna Adcock, NZ; Dr. Kendall Stevenson, NZ; Dr. Lisa Whop, Australia; Prof. Julia Brotherton, IPVS policy committee; Prof. Suzanne Garland A.O., IPVS policy committee Chair, IPVS Vice-President.

References


Australia (incidence 2.5X, mortality 4X); New Zealand (incidence 2X, mortality 2.5X); Canada (incidence < 3.5X, mortality 4X); USA (incidence < 2X, mortality < 4X).